186 related articles for article (PubMed ID: 30693647)
21. Treatment with 311-nm ultraviolet B enhanced response of psoriatic lesions in ustekinumab-treated patients: a randomized intraindividual trial.
Wolf P; Weger W; Legat FJ; Posch-Fabian T; Gruber-Wackernagel A; Inzinger M; Salmhofer W; Hofer A
Br J Dermatol; 2012 Jan; 166(1):147-53. PubMed ID: 21910714
[TBL] [Abstract][Full Text] [Related]
22. IL-20, IL-21 and p40: potential biomarkers of treatment response for ustekinumab.
Gedebjerg A; Johansen C; Kragballe K; Iversen L
Acta Derm Venereol; 2013 Mar; 93(2):150-5. PubMed ID: 22930279
[TBL] [Abstract][Full Text] [Related]
23. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: Results from the CLEAR study.
Blauvelt A; Reich K; Tsai TF; Tyring S; Vanaclocha F; Kingo K; Ziv M; Pinter A; Vender R; Hugot S; You R; Milutinovic M; Thaçi D
J Am Acad Dermatol; 2017 Jan; 76(1):60-69.e9. PubMed ID: 27663079
[TBL] [Abstract][Full Text] [Related]
24. Real-world outcomes in 2646 psoriasis patients: one in five has PASI ≥10 and/or DLQI ≥10 under ongoing systemic therapy.
Norlin JM; Calara PS; Persson U; Schmitt-Egenolf M
J Dermatolog Treat; 2017 Sep; 28(6):500-504. PubMed ID: 28132580
[TBL] [Abstract][Full Text] [Related]
25. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial.
Thaçi D; Blauvelt A; Reich K; Tsai TF; Vanaclocha F; Kingo K; Ziv M; Pinter A; Hugot S; You R; Milutinovic M
J Am Acad Dermatol; 2015 Sep; 73(3):400-9. PubMed ID: 26092291
[TBL] [Abstract][Full Text] [Related]
26. Secukinumab versus ustekinumab for skin clearance in patients with moderate to severe psoriasis after a year of treatment: Real-world practice.
López Jiménez P; Suárez Pérez J; Herrera Acosta E; Aguilera Arjona J; Mendiola Fernández MV; Bosch García R; Herrera Ceballos E
Dermatol Ther; 2019 Jul; 32(4):e12937. PubMed ID: 30983098
[TBL] [Abstract][Full Text] [Related]
27. Ustekinumab in the treatment of palmoplantar pustular psoriasis - a case series of nine patients.
Buder V; Herberger K; Jacobi A; Augustin M; Radtke MA
J Dtsch Dermatol Ges; 2016 Nov; 14(11):1108-1113. PubMed ID: 27879067
[TBL] [Abstract][Full Text] [Related]
28. Sustained Psoriasis Area and Severity Index, Dermatology Life Quality Index and EuroQol-5D response of biological treatment in psoriasis: 10 years of real-world data in the Swedish National Psoriasis Register.
Hjalte F; Carlsson KS; Schmitt-Egenolf M
Br J Dermatol; 2018 Jan; 178(1):245-252. PubMed ID: 28644904
[TBL] [Abstract][Full Text] [Related]
29. Health-related quality-of-life improvements during 98 weeks of infliximab therapy in patients with plaque-type psoriasis in real-world practice.
Shear NH; Hartmann M; Toledo-Bahena ME; Gilbert M; Katsambas A; Yao R; Popmihajlov Z
Qual Life Res; 2016 Aug; 25(8):2031-40. PubMed ID: 26869477
[TBL] [Abstract][Full Text] [Related]
30. Ustekinumab improves psoriasis-related gene expression in noninvolved psoriatic skin without inhibition of the antimicrobial response.
Baerveldt EM; Onderdijk AJ; Kurek D; Kant M; Florencia EF; Ijpma AS; van der Spek PJ; Bastiaans J; Jansen PA; van Kilsdonk JW; Laman JD; Prens EP
Br J Dermatol; 2013 May; 168(5):990-8. PubMed ID: 23278632
[TBL] [Abstract][Full Text] [Related]
31. Genetic variation at IL12B, IL23R and IL23A is associated with psoriasis severity, psoriatic arthritis and type 2 diabetes mellitus.
Eirís N; González-Lara L; Santos-Juanes J; Queiro R; Coto E; Coto-Segura P
J Dermatol Sci; 2014 Sep; 75(3):167-72. PubMed ID: 24957500
[TBL] [Abstract][Full Text] [Related]
32. Comparison of the 1- and 5-year effectiveness of adalimumab, etanercept and ustekinumab in patients with psoriasis in daily clinical practice: results from the prospective BioCAPTURE registry.
Zweegers J; Groenewoud JMM; van den Reek JMPA; Otero ME; van de Kerkhof PCM; Driessen RJB; van Lümig PPM; Njoo MD; Ossenkoppele PM; Mommers JM; Koetsier MIA; Arnold WP; Andriessen MPM; Kuijpers ALA; Berends MAM; Kievit W; de Jong EMGJ
Br J Dermatol; 2017 Apr; 176(4):1001-1009. PubMed ID: 27579864
[TBL] [Abstract][Full Text] [Related]
33. Impact of previous biologic use on the efficacy and safety of brodalumab and ustekinumab in patients with moderate-to-severe plaque psoriasis: integrated analysis of the randomized controlled trials AMAGINE-2 and AMAGINE-3.
Papp KA; Gordon KB; Langley RG; Lebwohl MG; Gottlieb AB; Rastogi S; Pillai R; Israel RJ
Br J Dermatol; 2018 Aug; 179(2):320-328. PubMed ID: 29488226
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and safety of ustekinumab in the treatment of moderate to severe plaque psoriasis in Singapore.
Chan WSA; Wong Y; Oon HHB; Theng CTS; Chong WS
Singapore Med J; 2023 Jul; 64(7):434-438. PubMed ID: 35196847
[TBL] [Abstract][Full Text] [Related]
35. Evaluation of expression pattern of selected genes associated with IL12/23 signaling paths in psoriatic patients during cyclosporine A therapy.
Grabarek BO; Wcisło-Dziadecka D; Michalska-Bańkowska A; Gola J
Dermatol Ther; 2019 Nov; 32(6):e13129. PubMed ID: 31631469
[TBL] [Abstract][Full Text] [Related]
36. Long-term efficacy and safety of ustekinumab, with and without dosing adjustment, in patients with moderate-to-severe psoriasis: results from the PHOENIX 2 study through 5 years of follow-up.
Langley RG; Lebwohl M; Krueger GG; Szapary PO; Wasfi Y; Chan D; Hsu MC; You Y; Poulin Y; Korman N; Prinz JC; Reich K;
Br J Dermatol; 2015; 172(5):1371-83. PubMed ID: 25307931
[TBL] [Abstract][Full Text] [Related]
37. Effects of tumor necrosis factor-α, interleukin-23 and interleukin-17A inhibitors on bodyweight and body mass index in patients with psoriasis.
Takamura S; Takahashi A; Inoue Y; Teraki Y
J Dermatol; 2018 Sep; 45(9):1130-1134. PubMed ID: 30004583
[TBL] [Abstract][Full Text] [Related]
38. Ustekinumab improves health-related quality of life in Korean and Taiwanese patients with moderate to severe psoriasis: results from the PEARL trial.
Tsai TF; Song M; Shen YK; Schenkel B; Choe YB; Kim NI; Lee JH; Lee JH; Song HJ; Youn JI;
J Drugs Dermatol; 2012 Aug; 11(8):943-9. PubMed ID: 22859239
[TBL] [Abstract][Full Text] [Related]
39. Quality of life and patient benefit following transition from methotrexate to ustekinumab in psoriasis.
Augustin M; Blome C; Paul C; Puig L; Luger T; Lambert J; Chimenti S; Girolomoni G; Kragballe K; Naessens D; Bergmans P; Smirnov P; Barker J; Reich K
J Eur Acad Dermatol Venereol; 2017 Feb; 31(2):294-303. PubMed ID: 27515070
[TBL] [Abstract][Full Text] [Related]
40. Association between clinical factors and dose modification strategies in the treatment with ustekinumab for moderate-to-severe plaque psoriasis.
Romero-Jimenez RM; Escudero-Vilaplana V; Baniandres Rodriguez O; García Martín E; Mateos Mayo A; Sanjurjo Saez M
J Dermatolog Treat; 2018 Dec; 29(8):792-796. PubMed ID: 29676189
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
